These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 18505403

  • 1. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [Abstract] [Full Text] [Related]

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ, Economopoulos K.
    Clin Trials; 2008 Dec; 5(2):116-20. PubMed ID: 18375649
    [Abstract] [Full Text] [Related]

  • 3. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.
    Am J Ther; 2008 Oct; 15(6):506-11. PubMed ID: 19127132
    [Abstract] [Full Text] [Related]

  • 5. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 6. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [Abstract] [Full Text] [Related]

  • 7. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [Abstract] [Full Text] [Related]

  • 8. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [Abstract] [Full Text] [Related]

  • 9. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J, Scheen AJ.
    Rev Med Suisse; 2007 Aug 29; 3(122):1876, 1878-83. PubMed ID: 17896661
    [Abstract] [Full Text] [Related]

  • 10. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb 29; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Feb 29; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 12. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.
    Arch Intern Med; 2008 Nov 24; 168(21):2368-75. PubMed ID: 19029503
    [Abstract] [Full Text] [Related]

  • 13. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov 24; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 14. PROactive: time for a critical appraisal.
    Betteridge DJ, DeFronzo RA, Chilton RJ.
    Eur Heart J; 2008 Apr 24; 29(8):969-83. PubMed ID: 18375395
    [Abstract] [Full Text] [Related]

  • 15. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Acta Diabetol; 2009 Jun 24; 46(2):145-54. PubMed ID: 19194648
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
    Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, PROactive Investigators.
    Diabetes Care; 2007 Nov 24; 30(11):2773-8. PubMed ID: 17666462
    [Abstract] [Full Text] [Related]

  • 17. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
    Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ.
    Am Heart J; 2011 Nov 24; 162(5):938-948.e2. PubMed ID: 22093212
    [Abstract] [Full Text] [Related]

  • 18. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 24; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 19. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.
    Pharmacoepidemiol Drug Saf; 2008 Aug 24; 17(8):769-81. PubMed ID: 18613278
    [Abstract] [Full Text] [Related]

  • 20. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb 24; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.